29 February 2024
Continued strong performance: accelerating growth, significant strategic progress, substantial returns to shareholders David Schwimmer, CEO said: “2023 was another strong year for LSEG. We…
28 February 2024
28 February 2024 The Renewables Infrastructure Group Limited“TRIG” or “the Company”, a London-listed investment company advised by InfraRed Capital Partners (“InfraRed”) as Investment Manager…
A YEAR OF PROGRESS WITH MID-SINGLE-DIGIT GROWTH IN HEALTH & HYGIENE Adjusted1 IFRS Unaudited £m 2023 vs 20222 Unaudited £m 2023 vs 20222 Full…
27 February 2024
Performance Highlights At At 31 December 2023 31 December 2022 Net assets £2,551,938,000 £2,417,967,000 Net asset value (“NAV”) per ordinary share (“share”) 1,598.0p 1,410.7p…
26 February 2024
26 February 2024 Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have…
GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC) · EAGLE-1 trial met its primary efficacy endpoint…
23 February 2024
BHP | Financial results for the half year ended 31 December 2023 20 February 2024 Financial results for the half year ended 31 December…
22 February 2024
22 February 2024 Acquisition of Gracell completed AstraZeneca today announced the successful completion of the acquisition of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage…